Doctoral fellow, Lab of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, UGent
Principal Investigator: prof. Katrien Remaut (PhD)
Yearly, about 150 000 people develop peritoneal carcinomatosis in Europe alone. During the standard treatment regimen patients receive intraperitoneal instillation of chemotherapeutics such as cisplatin after initial cytoreductive surgery. The clinical use of new administration techniques such as pressurized intraperitoneal aerosol chemotherapy (PIPAC) is however promising. Moreover, innovative pharmaceutical platforms such as nanoparticles and controlled release systems are thought to further boost locoregional drug delivery.
In this research project we will evaluate the potential of controlled release systems for the peritoneal delivery of chemotherapeutics, nanoparticles and biopharmaceuticals such as nucleic acids and antibodies. Therefore, we developed an ex vivo model to test the effect of high pressure nebulization of nanoparticles on isolated peritoneal tissue. Different controlled release systems will be evaluated in vitro and further optimized in vivo in a rat model of peritoneal carcinomatosis.
Contact & links
- Lab address: Lab of General Biochemistry and Physical Pharmacy, Ottergemsesteenweg 460, 9000 Ghent
- Lab of General Biochemistry and Physical Pharmacy
- Helena Braet is interested to receive invitations for presentations or talks